A Phase 1/2 interventional study of Recombinant herpes zoster vaccine with low-dose adjuvant and Recombinant herpes zoster vaccine with high-dose adjuvant in Herpes Zoster (HZ), sponsored by Shanghai Institute Of Biological Products. Recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.
Among the 51 studies in Herpes Zoster with a site in China, this one is the 20th largest by planned enrollment of the 45 interventional ones that give a count, is one of 20 that started in 2025, is one of 6 in phase 1/2, reaches primary completion later than 12 of the 30 other live ones, and was the 31st registered.
300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.
Browse Herpes Zoster studies →26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Sites in China
Ages 40+ · Healthy volunteers
Jiangsu Province Centers for Disease Control and Prevention · Sites in China
Ages 40+ · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 40+ · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 7 · Phase 4 6
First in 2011; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 645 is above the median of 160 across 248 interventional studies indexed under Herpes Zoster.
Median enrollment 519 across the 45 interventional studies, 187 across the 6 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Institute Of Biological Products, one of the names counted as Sinopharm. Under that name alone:
Shanghai Institute Of Biological Products is the lead sponsor of 34 studies on the registry; 14 are open to participants now.
Sinopharm has 4 studies filed under Herpes Zoster — fewer than ten, so there is no comparison to draw.
10 of the studies in Herpes Zoster with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06851832Ab&B Bio-tech Co., Ltd.JSClinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older | 2026-11-28 |
| NCT07099157Peking University Third HospitalEfficacy and Safety of Brivudine in the Treatment of Herpes Zoster | 2026-12-31 |
| NCT07361796Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster | 2027-09-30 |
| NCT07378046Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster | 2027-09-30 |
| NCT07378059Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster | 2027-09-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 51 studies in Herpes Zoster with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).
There are two parts of the study.
Substudy A:
This substudy is the Phase I portion of the study. In this substudy, participants will receive 1 of 2 RHZV candidates (different dose levels) or the approved shingles vaccine (positive control) or adjuvant controls or normal saline intramuscularly. Participants will be divided into 2 age groups: 40-49 years old and ≥ 50 years old. Participants will receive vaccinations on days 0 and 60. Participants will complete a 12-month safety follow-up after two doses of vaccination, and they will take part in this study for about 14 months.
Substudy B:
This substudy is the Phase Ⅱ portion of the study. In this part of the study, participants will also receive 1 of 2 RHZV candidates (different dose levels) or the approved shingles vaccine (positive control) or normal saline intramuscularly. Participants will be divided into 3 age groups: 40-49 years old, 50-69 years old and ≥ 70 years old. Participants will receive vaccinations on days 0 and 60. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants will be involved in this study for up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recombinant herpes zoster vaccine with low-dose adjuvant
Biological: Recombinant herpes zoster vaccine with low-dose adjuvant
Recombinant herpes zoster vaccine with high-dose adjuvant
Biological: Recombinant herpes zoster vaccine with high-dose adjuvant
Low-dose adjuvant
Biological: Low-dose adjuvant
High-dose adjuvant
Biological: High-dose adjuvant
Shingrix (GSK)
Biological: Shingrix (GSK)
Normal saline
Biological: Normal Saline
Recombinant herpes zoster vaccine with low-dose adjuvant
Biological: Recombinant herpes zoster vaccine with low-dose adjuvant
Recombinant herpes zoster vaccine with high-dose adjuvant
Biological: Recombinant herpes zoster vaccine with high-dose adjuvant
Shingrix (GSK)
Biological: Shingrix (GSK)
Normal saline
Biological: Normal Saline
Candidate 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
Candidate 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
Adjuvant control 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
Adjuvant control 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
Positive control, Intramuscular injection, 0, 2 months schedule
Placebo control, Intramuscular injection, 0, 2 months schedule
Percentage of immediate Adverse Events (AEs)
The occurrence of any adverse events within 30 minutes after each dose of vaccination.
Time frame: 30min after each dose of vaccination
Percentage of solicited Adverse Events
Adverse events defined by the protocol that occurred to the participant during 0-14 days after each dose of vaccination.
Time frame: 14 days after each dose of vaccination
Serious Adverse Events (SAE)
That is serious adverse events, any serious adverse events that occurred to the participant during the study period.
Time frame: 12 months after the last dose
Percentage of unsolicited Adverse Events
Other adverse events that occurred among participants within 0-28/30 days after each vaccination, in addition to the solicited adverse events.
Time frame: 28 or 30 days after each dose of vaccination
Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies
GMC levels o of Anti-gE Antibodies in participants after receiving 2 doses of vaccine.
Time frame: 30 days after the last dose of vaccination
Geometric Mean Titer (GMT) of Anti-VZV Antibodies
GMT levels o of Anti-VZV Antibodies in participants after receiving 2 doses of vaccine.
Time frame: 30 days after the last dose of vaccination
Positive rate of Anti-gE Antibodies
The proportion of individuals in the study population who have achieved Anti-gE antibody positive after immunization.
Time frame: 30 days after the last dose of vaccination
Positive rate of Anti-VZV Antibodies
The proportion of individuals in the study population who have achieved Anti-VZV antibody positive after immunization.
Time frame: 30 days after the last dose of vaccination
Seroconversion rate of Anti-gE Antibodies
The proportion of individuals in the study population who have achieved Anti-gE antibody seroconversion after immunization.
Time frame: 30 days after the last dose of vaccination
Seroconversion rate of Anti-VZV Antibodies
The proportion of individuals in the study population who have achieved Anti-VZV antibody seroconversion after immunization.
Time frame: 30 days after the last dose of vaccination
SSB: Cellular immune level
Levels of glycoprotein E (gE)-specific CD4+/CD8+ T cells expressing 2 or more markers of activation.
Time frame: 30 days, 6 months, 12months and 24 months after the last dose of vaccination
SSB:Humoral immunogenicity level
Levels of GMC (Anti-gE antibody), GMT (Anti-VZV antibody), positive rate and seroconversion rate after receiving 2 doses of vaccine.
Time frame: 6 months, 12months and 24 months after the last dose of vaccination
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Institute Of Biological Products →